OBI-3424 completes its phase 1 safety evaluation and demonstrates its safety with no major concerns, proceeding to phase 2 as planned

1. Date of occurrence of the event: April 21, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. Reciprocal shareholding ratios: Not applicable 5. Cause of occurrence: OBI-3424 completes its safety evaluation in phase 1 dose escalation and demonstrates its safety with no […]

This article is password protected.

To view the content, please enter your password in the field below